Anakinra + InfliximabContraindicated
Combination with TNF blockers including infliximab is not recommended due to increased risk of serious infections with no added clinical benefit.
Source: NLP:infliximab
Anakinra Interactions
Brand names: Kineret
Interleukin-1 Receptor Antagonist · Interleukin 1 Receptor Antagonists
Route: Subcutaneous
Contraindications
4 CONTRAINDICATIONS KINERET is contraindicated in patients with known hypersensitivity to E coli -derived proteins, KINERET, or any components of the product [see Hypersensitivity Reactions ( 5.3 )] . Known hypersensitivity to E coli -derived proteins, Kineret, or to any component of the product. ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary Available data from retrospective studies and case reports on KINERET use in pregnant women are insufficient to identify a drug associated risk of major birth defects, miscarriage, or maternal and fetal adverse events. There are risks to the mother and fetus associated with active rheumatoid arthritis or Cryopyrin-Associated Periodic Syndromes (CAPS). In animal reproduction studies, subcutaneous administration of anakinra to pregnant rats and rabbits during organogenesis demonstrated no evidence of fetal harm at doses up to 25 times the maximum recommended human dose (MRHD). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Published data suggest the risk of adverse pregnancy outcomes in women with rheumatoid arthritis or CAPS is associated with increased disease activity. Adverse pregnancy outcomes include preterm delivery (before 37 weeks of gestation), low birth weight (<2500 grams), and small for gestational age at birth. Data Human Data The available data from retrospective studies and case reports of anakinra-exposed pregnancies have not identified an increased frequency or pattern of birth defects, miscarriage, or adverse maternal or fetal outcomes. An international multi-center retrospective study of pregnancy outcomes with interleukin-1 inhibitors reported on 23 anakinra-exposed pregnancies. There were 21 live births of healthy infants, 1 miscarriage, and 1 infant with left renal agenesis. The estimated background rate of detected renal malformations is 0.2-2% of all newborns. Another retrospective study reported on 10 anakinra-exposed preg
31 interactions on record
Increased risk of serious infection when combined with TNF blockers; not recommended in RA patients.
Source: NLP:adalimumab
Increased risk of serious infection with no added benefit. Concomitant use not recommended in patients with RA.
Source: NLP:adalimumab-aaty
Increased risk of serious infection when combined with adalimumab-adaz. Use not recommended in patients with RA due to no added benefit.
Source: NLP:adalimumab-adaz
Increased risk of serious infection when combined with adalimumab-adbm. Concomitant use not recommended in patients with RA.
Source: NLP:adalimumab-adbm
Increased risk of serious infection when combined with TNF blockers. Use not recommended in patients with RA due to no added benefit.
Source: NLP:adalimumab-afzb
Increased risk of serious infection when combined with AMJEVITA. Concomitant use not recommended in RA patients.
Source: NLP:adalimumab-atto
Increased risk of serious infection when combined with HADLIMA; not recommended for RA patients.
Source: NLP:adalimumab-bwwd
Increased risk of serious infection when combined with adalimumab-ryvk. Not recommended in patients with RA.
Source: NLP:adalimumab-ryvk
Concomitant use decreases defactinib exposure, which may reduce the effectiveness of the drug combination. Avoid concomitant use.
Source: NLP:avutometinib potassium and defactinib hydrochloride
Triple combination with ACE inhibitor and mineralocorticoid receptor antagonist is generally not recommended. Monitor blood pressure, renal function, and electrolytes.
Source: NLP:candesartan
Triple combination with candesartan cilexetil and an ACE-inhibitor is generally not recommended due to increased risks of hypotension, hyperkalemia, and renal dysfunction.
Source: NLP:candesartan cilexetil
Increased risk of serious infections when used in combination with TNF-blocking agents. Combination therapy not recommended.
Source: NLP:certolizumab pegol
Anakinra + DasatinibMajor
Coadministration may decrease dasatinib concentrations and reduce efficacy. Do not administer with dasatinib.
Source: NLP:dasatinib
Concomitant use may result in serotonin syndrome. Frequently evaluate patient during treatment initiation and dose adjustment.
Source: NLP:hydromorphone hydrochloride
Concomitant use has resulted in serotonin syndrome.
Source: NLP:levorphanol tartrate
Concomitant use may result in serotonin syndrome. Carefully observe patient during treatment initiation and dosage modification; discontinue metaxalone if serotonin syndrome occurs.
Source: NLP:metaxalone
Concomitant use with opioids has resulted in serotonin syndrome.
Source: NLP:morphine sulfate
Concomitant use may result in serotonin syndrome. Carefully observe patient during treatment initiation and dose adjustment.
Source: NLP:nalbuphine hydrochloride
Gastric acid reducing agent. Decreases nirogacestat exposure, which may reduce effectiveness of nirogacestat.
Source: NLP:nirogacestat
Concomitant use has resulted in serotonin syndrome. Carefully observe patient during treatment initiation and dose adjustment.
Source: NLP:pentazocine and naloxone
Antagonistic effects with decreased phenylephrine blood pressure effect.
Source: NLP:phenylephrine hydrochloride
Concomitant use may result in serotonin syndrome.
Source: NLP:remifentanil hydrochloride
Concomitant use may reduce the effectiveness of taletrectinib by decreasing exposure.
Source: NLP:taletrectinib
Avoid concomitant use. If unavoidable, modify KOMZIFTI administration time to separate dosing.
Source: NLP:ziftomenib
Anakinra + DacomitinibModerate
Concomitant use may decrease dacomitinib concentrations. Administer VIZIMPRO at least 6 hours before or 10 hours after H2-receptor antagonist.
Source: NLP:dacomitinib
Anakinra + GlimepirideModerate
May increase glucose-lowering effect of glimepiride, increasing susceptibility to hypoglycemia.
Source: NLP:glimepiride
Anakinra + GlipizideModerate
May increase the glucose-lowering effect of glipizide, increasing susceptibility to hypoglycemia. Monitor closely.
Source: NLP:glipizide
Anakinra + KetoconazoleModerate
Reduce gastric acidity and impair ketoconazole absorption from tablets. Ketoconazole should be taken with acidic beverage during coadministration.
Source: NLP:ketoconazole
Anakinra + SelpercatinibModerate
Concomitant use decreases selpercatinib plasma concentrations, which may reduce anti-tumor activity. Avoid coadministration; if unavoidable, modify administration time.
Source: NLP:selpercatinib
Anakinra + AbataceptUnknown
Insufficient experience to assess safety and efficacy when administered concurrently. Use not recommended.
Source: NLP:abatacept